hengrui glp-1 Kailera, Push Oral GLP-1/GIP Pill to Phase 3 After Clearing Mid-Stage China Study Hengrui Pharma's GLP-1R Agonist Patent

All analyses were performed using the meta and metafor packages in R (version 4.3.0)

Funding This work was supported by the start-up funds for research from China Medical University (110/1210616002)

Ongoing Trials Current research continues to expand the understanding of GLP-1 RAs and their benefits in CVD, HF, and AF

GLP-1 users may differ from nonusers in ways that are not fully captured, such as socioeconomic status, health behaviors, disease severity, medication adherence, or access to care." Lakkis notes that the study also did not report how much weight participants lost, making it difficult to determine how much of the benefit may have been driven by weight reduction itself